UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

30-Jul-2015 - UCB announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical efficacy endpoints in either dose in both studies. Treatment response in patients who received epratuzumab in addition to standard therapy was not ...

Epratuzumab phase IIb data show pipeline drug had positive effect in patients suffering from systemic lupus erythematosus

11-Nov-2010 - UCB and U.S. based partner Immunomedics Inc.announced that results from the phase IIB study, EMBLEM™, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE. The ...

Karus Therapeutics Commences Preclinical Development of Novel Immune and Inflammation Programmes

03-Nov-2010 - Karus Therapeutics Ltd has commenced preclinical development of its HDAC6 and PI3-Kinase inhibitor programmes for the treatment of immune and inflammatory diseases such as rheumatoid arthritis (RA). Karus aims to initiate clinical trials for both programmes in 2011. Karus’s highly potent and ...

GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta

23-Aug-2010 - GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). A priority review designation is granted to ...

Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus

29-Jun-2010 - UCB and Immunomedics Inc. announced that data for lupus drug candidate, epratuzumab, were presented at the 9th International Congress on Systemic Lupus Erythematosus in Vancouver, Canada. These data showed that, in patients with moderate to severe systemic lupus erythematosus (SLE), epratuzumab ...

New data from EMBLEM study shows epratuzumab provided efficacy for patients suffering from systemic lupus erythematosus

17-Jun-2010 - UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the ...

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)

Data from phase IIb dose and regimen-ranging study demonstrate clinically meaningful treatment effect

28-Aug-2009 - UCB and Immunomedics announced top-line results from UCB's Phase IIb clinical study comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, also commonly known as lupus). The data from the 12-week dose and regimen-ranging study demonstrated clinical meaningful ...

Human Genome Science announces positive results of phase 2 clinical trial of Lymphostat-B in systemic lupus

16-Nov-2006 - Human Genome Sciences, Inc. announced that the 76-week results of a Phase 2 clinical trial demonstrated that LymphoStat-B(TM) (belimumab) reduced disease activity in patients with serologically active systemic lupus erythematosus (SLE), exhibited durable biological activity, and appeared safe and ...

Genelabs Announces Issuance of U.S. Patent on DHEA Composition and Method

15-Jun-2006 - Genelabs Technologies, Inc. announced the issuance of U.S. patent No. 7,045,513 entitled "DHEA Composition and Method." The patent claims pharmaceutical formulations of dehydroepiandrosterone, or DHEA, in certain purified polymorphic forms. DHEA is the active ingredient in Prestara(TM), the ...

FDA approves Rituxan as first targeted B-cell therapy for treatment of rheumatoid arthritis

02-Mar-2006 - Genentech, Inc. and Biogen Idec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan® (Rituximab) in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with ...